Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 12/20 | 0.48 |
| ▸ | S1PR3 | Q99500 | 12/20 | 0.48 |
| ▸ | S1PR2 | O95136 | 10/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 8/20 | 0.48 |
| ▸ | CETP | P11597 | 4/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.43 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130115 | 0.99 | S1PR1 (0.49) | S1PR1S1PR3S1PR2S1PR4CETP | |
| SCHEMBL6130099 | 0.89 | CETP (0.45) | S1PR1S1PR3S1PR2S1PR4CETP | |
| SCHEMBL6130097 | 0.85 | CETP (0.42) | S1PR1S1PR3S1PR2S1PR4CETP | |
| SCHEMBL23944942 | 0.81 | MBOAT4 (0.56) | CETPMBOAT4 | |
| SCHEMBL23318030 | 0.80 | MBOAT4 (0.55) | CETPMBOAT4 | |
| SCHEMBL6130110 | 0.78 | TNNC1 (0.46) | S1PR1S1PR3S1PR2S1PR4S1PR5 | |
| SCHEMBL6528663 | 0.76 | RARB (0.46) | S1PR1S1PR3S1PR2S1PR4S1PR5 | |
| SCHEMBL10955966 | 0.75 | MEN1 (0.48) | — | |
| SCHEMBL6130148 | 0.74 | MBOAT4 (0.43) | MBOAT4 | |
| SCHEMBL6130104 | 0.74 | SPHK2 (0.42) | S1PR1S1PR3S1PR2S1PR4S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1315735-A4 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO INC (US) | 2005-04-06 | — | — | EP | disclosed |
| EP-1315735-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | Merck & Co., Inc. (US) | 2003-06-04 | — | — | EP | disclosed |
| US-6437165-B1 | USEFUL FOR TREATING IMMUNE MEDIATED DISEASES AND CONDITIONS, SUCH AS BONE MARROW, ORGAN AND TISSUE TRANSPLANT REJECTION. | MERCK & CO., INC. | 2002-08-20 | — | — | US | disclosed |
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | MERCK & CO., INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002018395-A1 | PHOSPHATE DERIVATIVES AS IMMUNOREGULATORY AGENTS | MERCK & CO., INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091105-A1 | Phosphate derivatives as immunoregulatory agents | ALPP, PPIP5K2, ALPI | S1PR1 382/4885S1PR3 520/4885S1PR2 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.